Abarceo is a preclinical stage company. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
| Website | http://www.abarceo.com |
| Employees | 9 (4 on RocketReach) |
| Founded | 2017 |
| Technologies |
JavaScript
,
HTML
,
PHP
+4 more
(view full list)
|
| Industry | Biotechnology, Biotechnology Research, Science and Engineering, Pharmaceuticals, Pharmaceutical, Health Care, Therapeutics |
| Keywords | Preclinical Development, Pharmaceutical, Diabetes Research, Pharmaceutical Research, Biotechnology, Type 2 Diabetes, Drug Development, Drug Discovery, Molecular Biology, Diabetes Treatment, Biopharma, Genetic Research, Life Sciences, Clinical Trials, Clinical Stage |
| Competitors | Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Gilead Sciences +44 more (view full list) |
Looking for a particular Abarceo Pharma employee's phone or email?
Abarceo Pharma Questions
Adam Bruce is the CEO of Abarceo Pharma.
4 people are employed at Abarceo Pharma.
Top Abarceo Pharma Employees
Related Companies
G2Crowd Trusted
300K+
Plugin Users
